Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | EVP, Chief Regulatory Officer | March 03, 2025 | March 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date March 03, 2025 · Filed March 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,679 |
Reported balance
After 2025-03-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-03-03 · Sale · Disposed 1,059 · Balance 18,679 F1: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 3, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. F3: This amount includes 360 shares purchased under the Issuer's Employee Stock Purchase Plan on November 29, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 3, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
F3: This amount includes 360 shares purchased under the Issuer's Employee Stock Purchase Plan on November 29, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2025 Filed Mar 5, 2025 22:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,059 | $7.00 | $7,409.82 |
DisclosureSEC source: 0000905148-25-000863 · form4.xml · nonDerivative · entry 1 Henrich Jill · CIK 0001978096 · EVP, Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,679 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 3, 2025 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. F3 · balance_after: This amount includes 360 shares purchased under the Issuer's Employee Stock Purchase Plan on November 29, 2024. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 23:05 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 1,000 | $11.20 | $11,198.00 |
DisclosureSEC source: 0000905148-24-003243 · form4.xml · nonDerivative · entry 1 Henrich Jill · CIK 0001978096 · EVP, Chief Regulatory Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,378 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 18, 2024 and November 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 132 | $6.63 | $875.29 |
DisclosureSEC source: 0000905148-24-002302 · form4.xml · nonDerivative · entry 2 Henrich Jill · CIK 0001978096 · EVP, Global Head RA & Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,378 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 831 | $6.63 | $5,508.70 |
DisclosureSEC source: 0000905148-24-002302 · form4.xml · nonDerivative · entry 1 Henrich Jill · CIK 0001978096 · EVP, Global Head RA & Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,510 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. F3 · balance_after: This amount includes 4,284 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2024, and reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024. Read SEC document |
| May 16, 2024 Filed May 21, 2024 00:32 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 25,750 | $0.62 | $15,887.75 |
DisclosureSEC source: 0000905148-24-001557 · form4.xml · nonDerivative · entry 1 Henrich Jill · CIK 0001978096 · EVP, Global Head RA & Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 529,251 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 16, 2024 and May 17, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 23:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,879 | $0.72 | $2,792.88 |
DisclosureSEC source: 0000905148-24-000907 · form4.xml · nonDerivative · entry 1 Henrich Jill · CIK 0001978096 · EVP, Global Head RA & Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 555,001 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 4, 2024 and March 5, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 21:40 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 450,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-000111 · form4.xml · nonDerivative · entry 1 Henrich Jill · CIK 0001978096 · EVP, Global Head RA & Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 558,880 F1 · shares: These restricted stock units vest as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the second Quarterly Vesting Date (as defined below) following January 8, 2024, and as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the next seven Quarterly Vesting Dates, such that all of the shares shall be vested on the last Quarterly Vesting Date, subject to the reporting person's continuous service. "Quarterly Vesting Date" means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the Quarterly Vesting Date shall be the first business day after such date. F2 · balance_after: Includes 4,456 shares purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2023. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 22:29 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,267 | $0.39 | $1,270.86 |
DisclosureSEC source: 0000905148-23-001508 · form4.xml · nonDerivative · entry 1 Henrich Jill · CIK 0001978096 · EVP, Global Head RA & Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,424 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 22:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 558 | $1.65 | $922.93 |
DisclosureSEC source: 0001140361-23-040559 · form4.xml · nonDerivative · entry 2 Henrich Jill · CIK 0001978096 · EVP, Global Head RA & Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,691 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2023 and August 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 22:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,788 | $1.65 | $4,608.56 |
DisclosureSEC source: 0001140361-23-040559 · form4.xml · nonDerivative · entry 1 Henrich Jill · CIK 0001978096 · EVP, Global Head RA & Quality 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,249 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2023 and August 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.